Cancer Commons

As Childhood Cancer Awareness Month concludes, the 𝗕𝗿𝗮𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗮𝗻𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗔𝗹𝗹𝗶𝗮𝗻𝗰𝗲 (𝗕𝗖𝗦𝗦𝗔)—a collaboration between nonprofits Head for the Cure Foundation, the MUSELLA FOUNDATION FOR BRAIN TUMOR RESEARCH & INFORMATION INC., and Cancer Commons—proudly announces the appointment of a 𝗱𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗡𝗲𝘂𝗿𝗼-𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗡𝘂𝗿𝘀𝗲 𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗼𝗿, 𝗻𝗼𝘄 𝗮𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗽𝗿𝗼𝘃𝗶𝗱𝗶𝗻𝗴 𝗰𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝘀𝘂𝗽𝗽𝗼𝗿𝘁 𝗳𝗼𝗿 𝗯𝗿𝗮𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗿𝗲𝗴𝗶𝘃𝗲𝗿𝘀. Read the Press Release: bit.ly/CCBCSSANurse The newly established Nurse Navigator role is designed to offer specialized assistance, addressing both the psychological and practical needs of brain cancer patients and their families. This service ensures that patients receive timely guidance at every stage of their diagnosis and treatment, easing the complexities of care coordination and decision-making. 𝗛𝗲𝗹𝗽 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗻𝗱 𝗰𝗮𝗿𝗲𝗴𝗶𝘃𝗲𝗿𝘀: bit.ly/BCSSAGetHelp Brain tumors present unique challenges, demanding specialized care from diagnosis through treatment. With a shared commitment to addressing these challenges, the Brain Cancer Support and Solutions Alliance leverages the strengths of its member organizations to provide timely and personalized support. #BrainCancerSupportAndSolutionsAlliance #BCSSA #NurseNavigator #NeuroOncology #BrainCancer #BrainTumor #Glioblastoma #GBM #rGBM #DIPG #BTSM

Cancer Commons is seeking to fill an open position: Clinical Oncology Scientist (PhD). Please visit our website for detailed information: https://lnkd.in/gxa5djus We would love to hear from interested candidates. #Hiring

Here’s the latest from our Curious Dr. George! Read “The Personalized Power of the ‘N-of-1’ Approach” here: bit.ly/CCCDGNof1Sabin Curious Dr. George Lundberg, MD, discusses the value of the “n-of-1” approach—in which every patient with cancer is considered as the sole participant in their own clinical trial (an Nof1)—with Glenn Sabin, director of strategy and business development at Cancer Commons. Sabin is a 33-year cancer thriver and author of n of 1: One Man’s Harvard-Documented Remission of Incurable Cancer Using Only Natural Methods. #CuriousDrGeorge #Nof1 #Cancer #IntegrativeMedicine #PersonalizedOncology #PrecisionMedicine

PRESS RELEASE: 𝗕𝗿𝗮𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗮𝗻𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗔𝗹𝗹𝗶𝗮𝗻𝗰𝗲 𝗟𝗮𝘂𝗻𝗰𝗵𝗲𝗱 𝘁𝗼 𝗜𝗺𝗽𝗿𝗼𝘃𝗲 𝗖𝗮𝗿𝗲 𝗮𝗻𝗱 𝗢𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗳𝗼𝗿 𝗕𝗿𝗮𝗶𝗻 𝗧𝘂𝗺𝗼𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝘀 As Brain Tumor Awareness Month concludes, we are honored to share that Head for the Cure Foundation, the MUSELLA FOUNDATION FOR BRAIN TUMOR RESEARCH & INFORMATION INC, and Cancer Commons today announced the launch of the 𝗕𝗿𝗮𝗶𝗻 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝘂𝗽𝗽𝗼𝗿𝘁 𝗮𝗻𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗔𝗹𝗹𝗶𝗮𝗻𝗰𝗲 to provide support, education, and guidance to brain cancer patients and their caregivers. Read the Press Release here: bit.ly/CCBCSSAPressRelease Brain tumors present unique challenges, demanding specialized care from diagnosis through treatment. With a shared commitment to addressing these challenges, the Brain Cancer Support and Solutions Alliance will leverage the strengths of its member organizations to provide timely and personalized support. The alliance will take a significant step forward by hiring a neuro-oncology navigator, supported by a collaborative grant. The navigator will work within the Cancer Commons framework and provide swift responses to patient and caregiver inquiries and needs. #BrainCancerSupportAndSolutionsAlliance #BCSSA #BrainTumorAwarenessMonth #NeuroOncology #BrainCancer #BrainTumor #Glioblastoma #GBM #rGBM #DIPG #BTSM

Cancer Commons is seeking to fill two open positions: Clinical Oncology Scientist and Patient Navigator (Brain Cancer). Please visit our website for detailed information: https://lnkd.in/gVEjFSh3 We would love to hear from interested candidates.

Here’s the latest from our Curious Dr. George! Read “SAGE Oncotest: Entering the Next Generation of Tailored Cancer Treatment” here: bit.ly/CCCDGSageApfel For people with recurring or drug-resistant cancer, choosing the best-possible next treatment can pose a huge challenge. Our Curious Dr. George Lundberg, MD, asks Chris Apfel, MD, PhD, MBA—Founder, CEO, and Board Chair of SageMedic Corp.—about his company’s solution for many of these patients. #CuriousDrGeorge #CancerResearch #MolecularTesting #PersonalizedOncology #PrecisionMedicine #TargetedTherapy

Here’s the latest from our Curious Dr. George! Read “Treating Pancreatic Cancer: Could Metabolism—Not Genomics—Be the Key?” here: bit.ly/CCCDGSeyfried In 2018, we published a Curious Dr. George Lundberg, MD, post featuring Thomas Seyfried, PhD, about cancer possibly being mostly a metabolic—rather than genetic—disease. Since then, the field of cancer genomics has expanded enormously, and we have published many posts in support of better understanding and treatment of many types of cancer based on the genomic approach. In this Curious Dr. George post, Dr. Seyfried and two of his colleagues at Boston College—Derek Lee, MS, and Tomás Duraj, MD, PhD—provide an update on their perspective. #CuriousDrGeorge #PancreaticCancer #MetabolicTherapy

Here’s the latest from Curious Dr. George! Read “Protean BioDiagnostics: One Way to Access Full-Service Precision Oncology Testing” here: bit.ly/CCCDGProteanBioDx The use of advanced molecular testing of various cancers over the last 10-15 years has driven development of the field of precision oncology. Now, many patients with a variety of cancer types can benefit from targeted therapies. However, accessing precision testing and treatment can be a major challenge. Our Curious Dr. George Lundberg, MD, asks Anthony Magliocco MD, Founder and CEO of Protean BioDiagnostics, how his company enables better access. #CuriousDrGeorge #CancerResearch #MolecularTesting #MolecularDiagnostics #PersonalizedOncology #PrecisionMedicine #TargetedTherapy

Here’s the latest from Curious Dr. George! Read “How Would a Harvard Oncologist Manage His Own Metastatic Kidney Cancer?” here: bit.ly/CCCDGEinstein When facing a frightening new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Here, our Curious Dr. George Lundberg, MD, asks kidney cancer expert David J. Einstein, MD, how he would handle his own hypothetical case of kidney cancer. Dr. Einstein is Assistant Professor of Medicine in the Genitourinary Oncology Program at Harvard Medical School’s Beth Israel Deaconess Medical Center. #CuriousDrGeorge #KidneyCancer #RenalCancer #RenalCellCarcinoma #MetastaticRenalCancer

Here’s the latest from our Curious Dr. George! Read “How an Expert Would Manage His Own Stage 4 Pancreatic Cancer: An Update” here: bit.ly/CCCDGStrickler When confronted with a new cancer diagnosis, some people ask their doctors, “What would you do if you were me?” Previously, our George Lundberg, MD, asked John Strickler, MD, how he would handle his own hypothetical diagnosis of metastatic pancreatic cancer. Now, Dr. Strickler provides an updated answer, outlining new options for the nearly 95% of pancreatic cancer patients with KRAS mutations. Dr. Strickler is Associate Professor of Medicine in the Division of Medical Oncology at Duke University and Co-Leader of the Duke Molecular Tumor Board. #CuriousDrGeorge #PancreaticCancer #PanCan #KRAS #Pancreatic